Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease

Figures

• 

  FIGURE 1. Correlations between the percent change in the UPCR, the eGFR, and systolic BP from baseline. There was a positive correlation between the percent change in the UPCR and the percent change in the eGFR from baseline to 1 month after treatment. BP, blood pressure; eGFR, estimated glomerular filtration rate; UPCR, urinary protein‐to‐creatinine ratio. Spearman's rank correlation coefficients are shown.

• 

  FIGURE 2. Effect of Sac/Val on proteinuria. (A) Proportion of the percent change in the UPCR from baseline to 1 month of treatment (n = 66). (B) The trajectory of BP, the UPCR, and the eGFR in patients with an increased UPCR after treatment with Sac/Val (n = 35). Data are shown as the mean ± standard error. **p < 0.01, ***p < 0.001 versus baseline; †p < 0.05 versus 1 month after Sac/Val treatment. p values were adjusted by the Bonferroni method. BP, blood pressure; eGFR, estimated glomerular filtration rate; UPCR, urinary protein‐to‐creatinine ratio.

• 

  FIGURE 3. Effect of Sac/Val on the eGFR. (A) Proportion of the percent change in the eGFR from baseline to 1 month of Sac/Val treatment (n = 66). (B) The trajectory of BP, the UPCR, and the eGFR in patients with a ≥ 10% decline in the eGFR from baseline to 1 month after initiating Sac/Val (n = 12). Data are shown as the mean ± standard error. *p < 0.05, **p < 0.01 versus baseline. p values were adjusted by the Bonferroni method. BP, blood pressure; eGFR, estimated glomerular filtration rate; UPCR, urinary protein‐to‐creatinine ratio.